The common PARK8 mutation LRRK2 G2019S is not a risk factor for breast cancer in the absence of Parkinson's disease

Journal of Neurology

Volumn 260, Issue 8, 2013, Pages 2177-2178

  Mortiboys, H ^a   Cox, A ^b   Brock, I W ^b   Bandmann, O ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

BREAST CANCER; BREAST LESION; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CELL DIVISION; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; KIDNEY CARCINOMA; LETTER; MAMMOGRAPHY; MELANOMA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; THYROID CARCINOMA;

EID: 84881554444     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7027-7     Document Type: Letter

References (13)

1. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6(12):e1001257
2. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11(12):791-797
3. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henik B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Eng J Med 354:424-425
4. Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R, Djaldetti R, Nitsan Z, Ephraty L, Tunkel O, Kozlova E, Inzelberg L, Kaplan N, Fixler Mehr T, Mory A, Dagan E, Schechtman E, Friedman E, Hassin-Baer S (2012) The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 78(11):781-786
5. Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, Severt L, Hunt A, Raymond D, Ozelius LJ, Bressman SB (2010) LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord 25(15):2536-2541
6. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365(9457):415-416
7. Bandmann O, Cookson MR (2012) Parkinson disease, cancer, and LRRK2: causation or association? Neurology 78(11):772-773
8. Marín I, van Egmond WN, van Haastert PJ (2008) The Roco protein family: a functional perspective. FASEB J 22(9):3103-3110
9. Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP (2011) Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signalling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci USA 108(4):1439-1444
10. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr, North American Parkinson's and Melanoma Survey Investigators (2010) Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 67:347-352
11. Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Aharon-Peretz J, Milo R, Schwartz M, Huberman M, Gilead L, Barchana M, Liphshiz I, Fitzer-Attas C, Giladi N (2011) High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm 118:1199-1207
12. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH (2012) Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer 131(8):1904-1911
13. Kawate T, Iwaya K, Kikuchi R, Kaise H, Oda M, Sato E, Hiroi S, Matsubara O, Kohno N (2013) DJ-1 protein expression as a predictor of pathological complete remission after neo adjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 139(1):51-59